CA2340106A1 - Purification of blood clotting proteins - Google Patents

Purification of blood clotting proteins Download PDF

Info

Publication number
CA2340106A1
CA2340106A1 CA002340106A CA2340106A CA2340106A1 CA 2340106 A1 CA2340106 A1 CA 2340106A1 CA 002340106 A CA002340106 A CA 002340106A CA 2340106 A CA2340106 A CA 2340106A CA 2340106 A1 CA2340106 A1 CA 2340106A1
Authority
CA
Canada
Prior art keywords
fibrinogen
membrane
solvent stream
contaminant
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002340106A
Other languages
French (fr)
Inventor
Dennis Bryan Rylatt
Andrew Mark Gilbert
Chenicheri Hariharan Nair
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Life Therapeutics Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2340106A1 publication Critical patent/CA2340106A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/75Fibrinogen
    • CCHEMISTRY; METALLURGY
    • C02TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02FTREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F1/00Treatment of water, waste water, or sewage
    • C02F1/46Treatment of water, waste water, or sewage by electrochemical methods
    • C02F1/469Treatment of water, waste water, or sewage by electrochemical methods by electrochemical separation, e.g. by electro-osmosis, electrodialysis, electrophoresis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01LMEASURING FORCE, STRESS, TORQUE, WORK, MECHANICAL POWER, MECHANICAL EFFICIENCY, OR FLUID PRESSURE
    • G01L1/00Measuring force or stress, in general
    • G01L1/20Measuring force or stress, in general by measuring variations in ohmic resistance of solid materials or of electrically-conductive fluids; by making use of electrokinetic cells, i.e. liquid-containing cells wherein an electrical potential is produced or varied upon the application of stress

Abstract

A method of separating a blood clotting protein from a mixture of blood clotting protein and at least one contaminant, the method comprising: (a) placing a blood clotting protein and contaminant mixture in a first solvent stream, the first solvent stream being separated from a second solvent strea m by a first electrophoretic membrane; (b) selecting a buffer for the first solvent stream being a pH greater than the isoelectric point of the blood clotting protein; (c) applying an electric potential between the first and second solvent streams causing movement of at least some of the contaminants through the membrane into the second solvent stream while the blood clotting protein is substantially retained in the first solvent stream, or if enterin g the membrane, being substantially prevented from entering the second solvent stream; (d) optionally periodically stopping and reversing the electric potential to cause movement of any blood clotting protein having entered the membrane to move back into the first solvent stream, wherein substantially n ot causing any contaminants that have entered the second solvent stream to re- enter first solvent stream; and (e) maintaining step (c) until the first solvent stream contains the desired purity of blood clotting protein substantially mimicking the characteristics of natural blood clotting protei n.

Description

Purification of Blood Clotting Proteins Technical Field The present invention relates to methods for obtaining blood clotting proteins, particularly fibrinogen, in a substantially unmodified and natural state.
Background Art The conversion of fibrinogen to fibrin forms the infrastructure upon which other components of blood interact in haemostasis. Fibrin also has other functional roles in a myriad of physiological processes including wound healing, tumour growth and bone fracture repair. Purified fibrinogen is used as a haemostatic adjuvant in the production of fibrin glue used as a ''bandage' in various forms of surgery and has found particular roles in cardiovascular and neuro-surgery. The separation of fibrinogen from plasma, however, has always been a limiting factor in the fibrin glue industry and in 25 the research laboratory. Methods available currently can take up to three days with very poor yields, ranging from 40°Yo to 6096, dependant on the method used and the time taken. A major source of concern is the wastage of other potentially important proteins in blood that are discarded in the first purification step when using the frequently employed procedure of ethanol 2o precipitation.
Fibrinogen is only sparingly soluble in water but can also be readily salted out with neutral salts such as sodium chloride and ammonium sulphate. The characteristics of this clotting protein differs quite markedly from other proteins in that it has reduced solubility at low temperatures.
25 Fibrinogen can be precipitated with modest concentrations of PEG or water miscible organic solvents.
Traditional precipitation methods, however, have a number of disadvantages. Several proteins other than fibrinogen having similar physicochemical properties or binding affinity for fibrinogen and tend to 3o coprecipitate during precipitation. This contamination leads to the need for complex subsequent purification steps using different precipitating agents which seriously impair the yield of the purified fibrinogen and results in undesirable modification of the final product.
Although the starting material, plasma, can be obtained in large 35 amounts, the cost of the materials employed and the time taken to achieve purification are all important variables in considering which method should Received 28 March 2000 be commercially employed for the purification of fibrinogen. Presently, most commercial schemes for fibrinogen isolation are based on solubility properties of fibrinogen. The purification procedure employed by Kabi (Stockholm) includes alcohol precipitation, cryoprecipitation, barium sulphate adsorption, glycine extraction and acetone precipitation at low temperature. The result is 30-40% yield with high clottability.
Furthermore, the isolated or purified fibrinogen has characteristics dissimilar to natural fibrinogen in plasma (Nair et al 1986). A major determinant of the quality and functionality of a blood clot and also its role 1o as fibrin resides in the "nativity" of the fibrinogen. Nativity refers to the functionality and molecular similarity of the protein to that when it is in a physiological milieu. Current separation methods produce fibrinogen that is "harshly" treated using chemical and physical separation techniques that ultimately denature the fibrinogen i5 The present inventors have developed new methods for the purification of natural and functional fibrinogen.
Disclosure of Invention In a first aspect, the present invention consists in a method of separating fibrinogen having a functional characteristic of natural fibrinogen 2o from a mixture of a fibrinogen and at least one contaminant, the method COITlp1'lslIlg:
(a) placing a fibrinogen and contaminant mixture in a first solvent stream, the first solvent stream being separated from a second solvent stream by a first electrophoretic membrane;
?5 (b) selecting a buffer for the first solvent stream being a pH greater than the isoelectric point of the fibrinogen;
(c) applying an electric potential between the first and second solvent streams causing movement of at least some of the contaminants through the membrane into the second solvent stream while the fibrinogen is 30 substantially retained in the first solvent stream, or if entering the membrane. being substantially prevented from entering the second solvent stream:
(d) optionally periodically stopping and reversing the electric potential to cause movement of any fibrinogen having entered the membrane to move 35 back into the first solvent stream, wherein substantially not causing any IPEAIAU

Received 28 March 2000 contaminants that have entered the second solvent stream to re-enter first solvent stream: and (e) IIlalIltalIllng step (c) until the first solvent stream contains the desired purity of fibrinogen substantially mimicking the clotting characteristics of natural fibrinogen.
In a preferred embodiment, the method further includes the steps of:
(f) replacing the first electrophoretic membrane with a second electrophoretic membrane having a molecular mass cut-off greater than that of the first membrane:
(g) applying an electric potential between the first and second solvent streams causing movement of at least some of the contaminants through the second membrane into the second solvent stream while the fibrinogen is substantially retained in the first solvent stream, or if entering the second membrane, being substantially prevented from entering the second solvent stream:
(h) optionally periodically stopping and reversing the electric potential to cause movement of any fibrinogen having entered the second membrane to hove back into the first solvent stream, wherein substantially not causing any contaminants that have entered the second solvent stream to re-enter 2o first solvent stream: and (i) maintaining step (g) until the first solvent stream contains the desired purity of fibrinogen substantially II11n11Ck1Ilg the clotting characteristics of natural fibrinogen.
Preferably, the mixture is plasma obtained from blood. The invention is also suitable for processing plasma fractions obtained from human blood containing fibrinogen, cryo-precipitate or solvent precipitate from human plasma.
In a further preferred embodiment of the first aspect of the present invention, the first electrophoretic membrane has a molecular mass cut-off 3o close to the apparent molecular mass of fibrinogen, preferably about 300 kDa.
Preferably, the second electrophoretic membrane has a molecular mass cut-off greater than the first electrophoretic membrane, preferably about 1000 kDa.
The buffer pH of the solvent streams is preferably about 6Ø Major protein contaminants including albumin whose pI is 4.9 are separated from the fibrinogen as the contaminants are transferred into the second solvent AMENDED SHEET
tPE~4/AU
Received 28 March 2000 stream. A buffer particularly suitable for step (b) is Mes/Histidine pH 6Ø
It will be appreciated, however, that many other buffers would be suitable for use in the method according to the present 1I1V211t1011.
The present inventors have been able to obtain recoveries of fibrinogen from blood plasma of at least 70% and having about 95% clottability. The method is relative fast taking around 3 hours.
Further benefits of the method according to the first aspect of the present invention are the possibility of scale-up, and the removal of microbial pathogens/contaminants that may be present in the starting 1o material without adversely altering the properties of the purified fibrinogen.
In a second aspect, the present invention consists in use of GradiflowT"' technology in the purification and/or separation of fibrinogen substantially II11II11Ck1Ilg the characteristics of natural fibrinogen.
In a third aspect, the present IIIVeIltlOn COIISIStS IIl fibrinogen substantially mimicking the characteristics of natural fibrinogen purified by the method according to the first aspect of the present IIIVeI1t10I1.
In a fourth aspect, the present invention consists in substantially isolated fibrinogen substantially having the clotting and functional characteristics of natural fibrinogen.
2o In a fifth aspect, the present invention consists in use of fibrinogen according to the fourth aspect of the present invention in medical and veterinary applications.
It will be appreciated that the fibrinogen according to the present invention would be suitable for use in fibrin glue, isolating and researching Of flbl'lllOgell 111 dySflbrlIlOgeIlaeITllaS, inclusion of fibrin in vascular grafts and other wound healing aids.
In a sixth aspect, the present invention consists in a method of separating fibrinogen having a functional characteristic of natural fibrinogen frOlll a IIllXture 1I1C1ud1Ilg flbrlllOgell aIld at least One COIItamInaIlt, the fibrinogen and the at least one contaminant each having a respective size and a respective charge, the method comprising the steps of:
exposing the mixture to an electric field in the presence of an electrophoretic membrane having a defined pore size to thereby separate at least a portion of the fibrinogen and the at least one contaminant onto opposite sides of the membrane in accordance with differences in at least one AMENDED SHEET
tPEA/AU

Received 28 March 2000 of the size and charge between the fibrinogen and the at least one contaminant:
IIlalIltalIllllg the exposing step for a period not greater than 48 hours;
and 5 recovering from the mixture not less than 50% of the fibrinogen content of the mixture.
In a seventh aspect. the present invention consists in a method of separating fibrinogen having a functional characteristic of natural fibrinogen from a mixture including fibrinogen and at least one contaminant, the 1o fibrinogen and the at least one contaminant each having a respective size and a respective charge. the method comprising the steps of:
exposing the mixture to an electric field in the presence of an electrophoretic membrane having a defined pore size to thereby separate at least a portion of the fibrinogen and the at least one contaminant onto i5 opposite sides of the membrane in accordance with differences in at least one of the size and charge between the fibrinogen and the at least one contaminant:
lllalIltalIllllg the exposing step for a period not greater than 48 hours;
and 2o recovering from the mixture fibrinogen, wherein in a clotting test the fibrinogen produces fibrins in a clot having a mass to length ratio similar to that obtained with plasma in the salve clotting test.
In a eighth aspect. the present 1I1V811t1011 COIISIStS 111 a method of separating fibrinogen having a functional characteristic of natural fibrinogen ?5 from a mixture including fibrinogen and at least Olle COIltamlIlaIlt, the fibrinogen and the at least one cOIltan1111aI1t each having a respective size and a respective charge. the method comprising the steps of:
exposing the mixture to an electric field in the presence of an electrophoretic membrane having a defined pore size to thereby separate at 30 least a portion of the fibrinogen and the at least one contaminant onto opposite sides of the membrane in accordance with differences in at least one of the size and charge between the fibrinogen and the at least one COIItaI111Ilallt:
IIlalIltalIllIlg the exposing step for a period not greater than 48 hours;
35 and AMENDED SHEET
IPE~Q/AU
Received 28 March 2000 recovering from the mixture fibrinogen, wherein in a clotting test the fibrinogen produces a clot having fibrin network compaction similar to that obtained with plasma in the same clotting test.
In a ninth aspect. the present invention consists in a method of separating fibrinogen having a functional characteristic of natural fibrinogen from a mixture including fibrinogen and at least one contaminant, the fibrinogen and the at least one contaminant each having a respective size and a respective charge, the method comprising the steps of:
exposing the mixture to an electric field in the presence of an electrophoretic membrane having a defined pore size to thereby separate at least a portion of the fibrinogen and the at least one contaminant onto opposite sides of the membrane in accordance with differences in at least one of the size and charge between the fibrinogen and the at least one contaminant;
maintaining the exposing step for a period not greater than 48 hours;
and recovering from the mixture a fibrinogen having a purity of not less than 90%.
The inventors have found that the present invention is particularly 2o suitable for fibrinogen separation. It will be appreciated, however, that other blood clotting proteins, including thrombin, factor VIII, alpha 2 macroglobulin and plasminogen would also be expected to be separated in a more natural state by the present invention.
Throughout this specification, unless the context requires otherwise, the word "comprise". or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element. integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.
In order that the present invention may be more clearly understood, preferred forms will be described in the following example with reference to the accompanying drawing.
AMENDED SHEET
~PEAIAU
Brief Description of Drawings Figure 1 is a schematic representation of pore size separation/purification achieved by GradiflowT" technology.
Figure 2 shows native SDS PAGE analysis of a fibrinogen purification process according to the present invention, where Lane 1: Molecular weight markers; Lane 2: Plasma; Lane 3: Upstream 1 hour; Lane 4: Upstream 90 minutes; Lane 5: Upstream 2 hours; and Lane 6: ADI Grade L Fibrinogen.
Figure 3 shows Western analysis of a fibrinogen purification process according to the present invention, where Lane 1: Plasma; Lane 2: Upstream 1 hour; Lane 3: Upstream 90 minutes; Lane 4: Upstream 2 hours; Lane 5:
Upstream 2 hours lyophilised; and Lane 6: ADI Grade L Fibrinogen.
Figure 4 shows reduced SDS PAGE analysis of a fibrinogen purification process according to the present invention where Lane 1: Molecular weight markers; Lane 2: ADI Grade L Fibrinogen; Lane 3: Plasma; Lane 4: Upstream 1 hour: Lane 5: Upstream 2 hours; and Lane 6: ADI Grade L Fibrinogen Figure 5 shows clotting curves of plasma, a sample of fibrinogen produced according to the present invention, and a commercial sample of fibrinogen.
Figure 6 shows PAGE analysis of fibrinogen purification from cryo-precipitate 1 where Lane 1: Molecular weight markers; Lane 2: Cryo-precipitate 1; Lane 3: Upstream 1 hour; Lane 4: Upstream 2 hours; Lane 5:
Upstream 3 hours; Lane 6: Downstream zero; Lane 7: Downstream 1 hour;
Lane 8: Downstream 2 hours; Lane 9: Downstream 3 hours; and Lane 10: ADI
Grade L Fibrinogen.
Modes for Carryin~ Out the Invention METHODS
Gradiflow~' technology The GradiflowT" comprises of three separate flow streams (sample, product and buffer) that feed into the membrane cartridge housed inside the 3o separation unit where they are sandwiched between porous polyacrylamide membranes.
Some additional aspects of the Gradiflowr" technology are further described in US Patent No 5,039,386 and US Patent No 5,650,055, which US
Patents are owned by the owners of the present invention and which US
Patents are hereby incorporated by reference.
Gradiflow'~ principle Proteins exist as charged molecules above or below their isoelectric point (pI). In the Gradiflow'", the net charge on a macromolecule is controlled by the choice of buffer pH. The proteins are separated in an electric field by charge and/or size differences.
Charge and/or size based separations It has now been demonstrated by the present inventors that one of the great advantages of the GradiflowT" separation system is that a protein can be separated based on the dual characteristics of size and charge. For charge-based separations, a pH is selected between the isoelectric points of two proteins such that one protein will have a positive charge and the other a negative charge. In the example illustrated in Figure 1, a protein mixture continuously circulates in the upstream compartment. When an electrical potential is applied, the negatively charged molecules migrate across the s5 separation membrane to the downstream towards the positive electrode under the influence of an electric field. All other molecules are retained in the upstream. Altering the pore size of the intervening separation membrane allows separations to be performed by size and/or charge.
Purification of fibrinogen Phase 1 In one particular example, whole blood was collected in 3.8~o sodium citrate in a ratio of 9 parts blood to 1 part anticoagulant. The blood was then centrifuged at 60008. The resultant supernatant was centrifuged again at 30008 to give essentially platelet poor plasma (PPP) ( < 3000 platelets/wl).
Each sample of PPP was then diluted with three volumes of 80g.M Tris Borate buffer (pH 8.5). This same buffer was selected as the running buffer. A
buffer pH of 8.5 ensured that most of the proteins in plasma had a negative charge, including fibrinogen. A GradiflowT" separation cartridge with a molecular mass cut off of 300 kDa was selected, as this would ensure that all other proteins below 300 kDa would be separated from plasma when the electrical field was turned on. The Phase one separation according to this example was run for 1 hour with the downstream harvested every 20 minutes and replaced with fresh buffer. A maximum voltage of 250V and maximum current of 1A was applied across the cartridge.
Phase 2 In this example, the isolated protein mixture from the upstream of Phase 1 was used in Phase 2. Separation was achieved using running conditions identical to those used in Phase 1, except that the separation membrane had a 1000 kDa cut off. The Gradiflow"" was run for 1 hour with the downstream harvested every 20 minutes and replaced with fresh TB.
This strategy enabled the removal of proteins in plasma with a molecular weight greater than 300 kDa.
Phase 3 The upstream product of Phase 2 was further processed in this example at pH 6.0 using a MES/Histidine buffer. The GradiflowT" system was run for 1 hour at 300V reversed polarity with a 1000 kDa cut-off separation membrane and the downstream removed for analysis. The upstream was harvested for further analysis. This exemplary strategy z5 enabled the removal of IgG contamination as the immunoglobulins were charged at pH 6.0 and migrated across the separation membrane and away from the fibrinogen sample.
Characterisation of fibrinogen SDS PAGE, native PAGE (Laemmli, 1970) and Western blot analysis (Towbin et al, 1979) were carried out on sample from both the up and down streams in the examples of the present invention. All electrophoresis gels were Gradipore T"' Tris-glycine gels.
SDS PAGE
SDS PAGE was performed using Tris-glycine-SDS running buffer, SDS
PAGE samples were prepared using 40 microlitres Gradipore ~' glycine sample buffer, 10 microlitres DTT, 50 microlitres sample and were boiled for 5 minutes. SDS PAGE was run at 150V and 500mA for 90 minutes.
Native PAGE
Native PAGE was performed using Tris-glycine running buffer. Native 3o PAGE samples were prepared using 25 microlitres native sample buffer and 50 microlitres sample. Native PAGE was run at 200V and 50mA for 90 minutes.
All SDS and native PAGE were stained with Gradipure T"' (coomassie stain) (Gradipore, Sydney, Australia).
Western analysis Western analysis was carried out as described by Towbin et al (1979) on selected SDS and native PAGE. Blotting filter paper and nitrocellulose blotting membrane were pre-soaked in Towbin buffer for 60 minutes. Protein transfer was performed in semi-dry blotting apparatus (Macquarie University, 5 Sydney Australia) at 12V for 90 minutes. The membrane was washed with PBS for 5 minutes, blocked with 1% skim milk in phosphate buffered saline for 10 minutes. The membrane was stained with 20 ~,1 rabbit anti-human fibrinogen conjugated to horseradish peroxidase (HRP) (DAKO A/S, Denmark) in 10 ~1 1% skim milk solution for 60 minutes. The stain was developed with s0 4CN diluted one part in five in PBS to a volume of 10 ml and 10 microlitres HZOZ. Development of the blot occurred within 30 minutes.
Sample concentration was performed using an Amicon stirred cell ultrafiltration apparatus (Amicon). The fibrinogen sample, with an initial volume of 60 mL was placed in the pressure chamber with pressure of 50 psi and concentrated using a 30 kDa cut off membrane and collected in a beaker.
The pH of the concentrate was adjusted to 7.3 for clotting assays.
Fibrinogen recovery An in-house enzyme-linked immunoassay (EIA) was used to quantitate the recovery of fibrinogen through the GradiflowT"' purification process.
2o Anti-human fibrinogen monoclonal antibody 3D5 (supplied by AGEN, Queensland, Australia) in PBS and 0.5% sodium azide was applied to the ELISA plate and incubated at room temperature for 1 hour. At the completion of the incubation, the plate wells were washed three times with PBS/Tween 20 for two minutes. Fibrinogen standards (American Diagnostica, Grade L) and GradiflowT" fibrinogen samples were applied to appropriate wells and the plate was incubated on a shaker for 20 minutes.
The plate was again washed three times with PBS/Tween 20 for two minutes.
The secondary antibody, rabbit and human fibrinogen conjugated to HRP
(DAKO A/S, Denmark), was applied and allowed to incubate on a shaker for 20 minutes. The plate was then washed three times with PBS/Tween 20 for two minutes. Samples were then developed using ABTS solution and 3%
HZO for 20 minutes and stopped with 3.9% oxalic acid. The plate was read with an ELISA plate reader (BioRad, USA) Fibrinogen characterisation Thrombin clotting curves Clotting curves were generated to illustrate the conversion of GradiflowT'" fibrinogen to fibrin. To 0.9 mL fibrinogen solution was added 0.1 mL thrombin/calcium mixture (final concentrations of 0.5 wl/mL thrombin (Bovine Thrombin, Sigma, USA) and 10 mM CaCl2). The progression of polymerisation was observed using optical density readings at 600nm plotted against time.
Clotting curves of GradiflowT" fibrinogen, a fibrinogen standard and 20 plasma were compared.
Mass to length ratio Mass to length ratio (Carr and Hermans 1976) was used to quantitate fibrin fibre thickness of fibrin network structures. To 0.9 mL fibrinogen solution was added 0.1 mL thrombin/calcium mixture (final concentrations of 10 wl/mL thrombin and 10 rnM CaCl2) and left at room temperature for 1 hour for clot stabilisation. Optical density readings were recorded at 800nm with unclotted fibrinogen used as the reference. Mass to length ratio (~,1.) of fibrin fibres was calculated from measurements of turbidity at 800nm and is given by:
ur =
clottability * c where T represents the turbidity of the fibrin matrix and is calculated by multiplying the optical density at 800nm by el and c is the concentration of fibrinogen in solution. The units of fibrin fibre thickness are Daltons/cm.
The mass to length ratio of Gradiflow"" fibrin fibres was compared with that of plasma, and a commercial standard.
Compaction (Nair et al 199?) Fibrin networks were prepared from plasma, purified fibrinogen 3o solutions (ADL, USA) and GradiflowT'° fibrinogen, in 1.5 mL
eppendorf microfuge tubes, pre-sprayed .with a lecithin based aerosol. To each 0.9 mL
fibrinogen solution was added to 0.1 mL thrombin/calcium mix (final concentrations of 10 NIH units/mL thrombin and 10 mM CaClz) and left at room temperature for 1 hour for clot stabilisation. The networks were 34.59*T*10 centrifuged at 8000 x g for 1 minute in a microcentrifuge (Zentrifuge 3200, Eppendorf, Germany). The volume of the supernatant expelled from the network was measured with a 1 mL Hamilton glass syringe and expressed as a percentage of the initial network volume.
RESULTS
s Fibrinogen purification Figure 2 is a native PAGE of an example of a purification according to the present invention. Lanes 3 and 4 illustrate the removal of contaminating proteins using 80 mM Tris Borate (pH 8.4) running buffer from plasma (Figure 2, lane 2).
In this example, the pH of the buffer resulted in all components of plasma with a pI below 9.0 becoming negatively charged. Conversely, all proteins with a pI higher than 9.0 were positively charged. When a voltage was placed across the separating membrane (300 kDa cut off), charged species migrated toward the electrode of opposite charge. Most protein z5 contaminants were removed within one hour. Although fibrinogen was charged, the low charge to mass ratio placed upon the molecule at pH 9.0 resulted in the slow migration of the molecule. Added to this was the difficulty encountered in moving fibrinogen (34 kDa) across any separating membrane. The difficulty was attributed to the elongated shape of fibrinogen. Fibrinogen's Stokes radius makes it appear much larger when it is pushed through membrane pores than is molecular mass dictates.
Furthermore, fibrinogen self associates, forming lager molecular weight aggregates that cannot migrate through the separation membrane.
Phase 2 of the fibrinogen purification was carried out in TB buffer at pH 9Ø The high salt concentration (80 mM) assisted in retaining fibrinogen in solution throughout the procedure. The high pH utilised resulted in most of the protein contaminates present becoming negatively charged. The pore size of the second separation membrane (1000 kDa cut off) did not restrict the migration of most of the low molecular weight proteins that were present after the citrate buffer purification whilst at the same time restricting the migration of fibrinogen into the waste stream.
Western analysis of examples of GradiflowT" fibrinogen confirmed the presence of fibrinogen initially observed in both reduced and native gels. In the present example, Western blot (Figure 3) illustrates the progression of fibrinogen. through the two phases of the purification protocol. Lane 1 illustrates the presence of large volumes of impurities with the fibrinogen bands appearing bloated by interference from albumin. It is evident in this example after phase 1 of the purification that the albumin was removed resulting in the fibrinogen bands becoming far more defined (Figure 3, lane 2).
The presence of plasminogen in the fibrinogen was confirmed with the use of plasminogen standard solution, run adjacent to the fibrinogen solution on both reduced SDS PAGE and native PAGE. Plasminogen has in the past been one of the protein contaminants in fibrinogen solutions that has proved difficult to remove without a separate procedure. This can be explained by specific binding of fibrinogen) and plasminogen in blood plasma. Lysine sepharose affinity columns have been traditionally used to remove plasminogen.
Other contaminating protein components could also be visualised by PAGE in this example. The low molecular band in the reduced PAGE (Figure 3) is believed to be the light subunit chain of IgG. The high pI range of IgG
(6-9) resulted in little or no charge of the molecule at pH 8.5. Phase 3 removed this contamination using a charged-based separation strategy at pH

The remaining contaminants were not removed in the initial two phases of the purification for one of three reasons.
Firstly, the pI of the contaminants may have been somewhat close to or above pH 8.5, the pH of the TB separation buffer utilised in the isolation. An unusually high isoelectric point may have resulted in the contaminants not becoming negatively charged at pH 8.5, hence the contaminants were not attracted to the positive electrode through the separation membrane.
Secondly, the size of the contaminants may not have been as large or larger than that of fibrinogen and, as a result, their migration across the separation membrane was restricted by the pore size of the membrane.
Finally, the contaminating components of the preparation may have been members of a fibrinogen complex in vivo. That is, the contaminants were physically bound to fibrinogen in its physiological state, and their close relationship with fibrinogen was of biological importance. The buffers utilised in the isolation were so mild that the fibrinogen isolated was done so with other bound components, as a single entity, as it is found in plasma.
The intimate relationship of the contaminating proteins and fibrinogen was not disturbed by the purification procedure.

As the Gradiflow'"' was used to isolate native fibrinogen in these examples, the contaminants present on the reduced and native gels may in fact be proteins that bind to fibrinogen in vivo. The presence of these proteins may be essential for biological functionality. Prior art fibrinogen preparations presently commercially available attempt to remove these components from solution in the process reducing the nativity of the fibrinogen and hence the final network produced when it polymerises.
Examples of fibrinogen purifications demonstrated in this specification were completed in approximately three hours. These recoveries are in contrast to prior art fibrinogen isolation methods that are completed in about 72 hours. The Gradiflow~' method for blood clotting proteins allowed a rapid separation of fibrinogen having the desired nativity.
The addition of serine protease and calcium ions resulted in the formation of a visible clot in the fibrinogen solution in the examples, thus confirming that clotting activity was retained in Gradiflowr"-isolated fibrinogen. Further studies on some of the examples were carried out characterising the network structure of the insoluble gel formed upon thrombin and calcium addition.
Fibrinogen recovery 2o Conventional fibrinogen purification protocols recover approximately 35% to 40% of the fibrinogen content of plasma (Furlan 1984). Industrially, fibrinogen yields are closer to 6% with losses commonly attributed to the use of complex procedures during which fibrinogen was co-precipitated and co-eluted with contaminating proteins. In contrast, use of the Gradiflow'"
technology for separation of blood clotting proteins, fibrinogen yield is over 72%. This provides an unexpected and advantageous advance over the prior art purification schemes. Tables 1 and 2 compare examples of fibrinogen recovery using the Gradiflow?"' to conventional protocols.

Table 1: Summary of comparison of commercially available fibrinogen with fibrinogen isolated by the GradiflowT" technology Com arators *Commercial Fibrino GradiflowT"
en Separation time 48 - 72 hours 3 hours Separation media harsh chemicals mild buffers Co-precipitation Yes No Yield 30 - 40% > 709'6 Purity (SDS PAGE)90% 95Yo Clottability High High Solubility Low High Nativity No Yes Vector and bacterial removal Separate procedure Achievable Cost High Low 5 *Furlan, M (1984).
Table 2. Fibrinogen yield comparison Sample Yield (%
GradiflowT"' 79 Conventional purification 40 Commercial preparation 10 10 Characterisation of Gradiflow~' fibrinogen The nativity of fibrinogen is best measured by the structure of the matrix produced when clot is formed. Close similarity with a blood clot indicates that the preceding fibrinogen is as found in plasma. Fibrin fibre thickness and the tensile strength of the clot were two characteristics 15 investigated in an attempt to compare the nativity of GradiflowT"
fibrinogen with plasma fibrinogen and a commercial preparation produced using precipitation, column chromatography and traditional electrophoresis.

Clotting curves describe the conversion of fibrinogen to fibrin with the addition of thrombin. The initial lag phase indicates the time taken for the conversion of fibrinogen to activated fibrin monomers. This is described as the clotting time of fibrinogen and is indicative of fibrinogen activity. The rate of rise phase proceeding this phase illustrates the rate of polymerisation of fibrin monomers and results in the production of a stable clot as described by the plateau of the curve.
Figure 5 illustrates the production of a clot from plasma, GradiflowT"
fibrinogen from one of the examples and a commercial standard. It is evident that the clotting times and rate of rise for GradiflowT" fibrinogen and the commercial standard differ markedly from that of plasma. The similarity of the stable plasma clot and that of a Gradiflow'" fibrin network, however, is indicative of the similarity of GradiflowT" fibrinogen with that found in native plasma.
Mass to length ratio Mass to length ratio is a biophysical assay, measuring the thickness of fibrin fibres when clotted with thrombin. The removal of fibrino-peptides is a kinetic process that results in the polymerisation of activated fibrin molecules. There are several factors that influence the physical nature of 2o clot fibres, including fibrinogen and thrombin concentrations, calcium ion concentration and the presence of other protein components in the fibrinogen solution.
Clot fibre characteristics are a measure of the preceding fibrinogen nativity. Blood plasma contains all of the required elements for the production of a fully effective clot. Blood clots contain fibrin fibres that are coarse and numerous, a result of complex interactions from hundreds of blood components including platelets, fibronectin and plasminogen. When clotted, purified fibrinogen solutions produce fibrin fibres that are relatively fine and sparse. This contrast with blood clots is attributed to the removal of essential related elements from the surrounding environment and a subsequent alteration of the kinetics of clot formation.
Table 3 illustrates the difference in mass to length ratio of a plasma clot and that produced from a commercial fibrinogen standard. Gradiflow~' fibrin fibres were thicker than those produced from the commercial preparation, suggesting that the example of the Gradiflowr" fibrinogen is more like plasma fibrinogen than current commercial preparations.

Table 3. Mass to length ratios, a measure of fibrin fibre thickness Sample Ratio Plasma 65 Gradiflow~" I 35 Commercial preparation ~ 20 Fibrin fibre comparison of different fibrinogen solutions is a good indicator of fibrin nativity, however, in conjunction with clot compaction a more detailed explanation of fibrin network structure can be obtained.
Compaction Compaction is an indicator of the tensile strength of fibrin network structures. The cross-linking of adjacent fibrin fibres provides a clot with its characteristic network structure and results in the matrix retaining form when placed under physiological stresses. Commercial fibrinogen separations clot to form a structure that is high in tensile strength and as a result they do not act in the same manner as a blood clot when placed in situ.
The nativity of Gradiflowr" fibrinogen is illustrated by the compaction of a clotted sample (Table 4). The manner in which it acts to stresses is similar to that of blood plasma and this was attributed to the isolation of a fibrinogen complex as is found as it is found irt vivo.
Table 4. Fibrin network compaction comparison Sample ~ Expelled Supernatant Plasma 55 Gradiflowr" ~ 60 Commercial preparation ~ 30 Compaction of a fibrin matrix is observed by collapsing a clot under uniform gravitational force. The level of collapse is indicative of fibrin fibre cross-linking in network organisation.

The collective organisation of fibrin fibres is indicative of the kinetic process of fibrin polymerisation and clot stabilisation. In vivo, factor XIli assists in the cross-linking of fibres to produce a network that can resist physiological stresses. Traditional purification schemes for fibrinogen attempt to remove all contaminants from solution resulting in a polymerisation process that is not similar to the complex coagulation process of blood.
Fibrinogen isolation from cryo-precipitate 1 Fibrinogen is conventionally purified from plasma by a series of techniques including ethanol precipitation, affinity columns and traditional electrophoresis. This process takes about 48-72 hours and the harsh physical and chemical stresses placed on fibrinogen are believed to denature the molecule, resulting in activity that is removed from that of fibrinogen in plasma.
Cryo-precipitation is the first step in the production of factor VIII and involves the loss of most of the fibrinogen in plasma. Processing of this waste fibrinogen is of considerable interest to major plasma processors and provides an opportunity to demonstrate the rapid purification of fibrinogen from cryo-precipitate using the method according to the present invention.
In this example, cryo-precipitate 1, produced by thawing frozen plasma at 4°C overnight was removed from plasma by centrifugation at 10000xg.
The precipitate was re-dissolved in 80 mM Tris-Borate buffer (pH 8.5) and placed in the upstream of a GradiflowT"' apparatus. A potential of 250 volts was applied across a 1000 kDa cut-off cartridge and run for 1 hour. The downstream was replaced with fresh buffer at 30 minute intervals. The buffer was replaced after phase 1 with a Histidine/MES buffer (pH 6.0) and the apparatus was run at 250 volts reversed potential for a further 1 hour.
The downstream was again harvested at 30 minute intervals and replaced with fresh running buffer. The upstream was harvested and concentrated using an Amicon stirred cell ultrafiltration cell. The product was analysed for clotting activity by the addition of thrombin and calcium (final concentrations (10 NIH unit/mL and 10 mM respectively).
Purity of the sample was investigated using reduced SDS PAGE and the presence of fibrinogen confirmed with western analysis. Western blots were stained with DAKO rabbit anti-human fibrinogen conjugated to HRP
and developed with 4CN.

Fibrinogen estimation was performed using an in house EIA.
The results of the purification procedure are shown in Figure 6. The final fibrinogen product had characteristics of native fibrinogen and was substantially indistinguishable from fibrinogen obtained from whole blood by the method according to the present invention.
GradiflowT" technology allows the rapid purification of fibrinogen from plasma. The fibrinogen appears to retain much of its native characteristics and biological function. The process according to the present invention is scalable and introduces a new and useful means of purifying blood products with high yield and virtually no wastage.
It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

References Towbin, 1979. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proceedings of the National Academy of Sciences of the USA
5 76: 4350.
Nair CH and Shah EA 1997. Compaction as a method to characterise fibrin network structure: kinetic studies and relationship to crosslinking.
Thromb Res 88: 381.
Carr ME jr and Hermans J, 1978. Size and density of fibrin from 10 turbidity. Macromolecules 11: 46.
Laemlii, 1970 Nature, 227: 680.
Furlan M, 1984. Purification of Fibrinogen in Beck EA and Furlan M
(Eds), Variants of Human Fibrinogen. Hans Huber Publications Berne, pp 133-145.
15 Shah GA, Nair, CH, Dhall D P (1987). Comparison of fibrin networks in plasma and fibrinogen solution. Thrombosis Research 45: 257

Claims (16)

CLAIMS:
1. A method of separating fibrinogen having a functional characteristic of natural fibrinogen from a mixture of fibrinogen and at least one contaminant, the method comprising:
(a) placing fibrinogen and contaminant mixture in a first solvent stream, the first solvent stream being separated from a second solvent stream by a first electrophoretic membrane;
(b) selecting a buffer for the first solvent stream being a pH greater than the isoelectric point of the fibrinogen;
(c) applying an electric potential between the first and second solvent streams causing movement of at least some of the contaminants through the membrane into the second solvent stream while the fibrinogen is substantially retained in the first solvent stream, or if entering the membrane, being substantially prevented from entering the second solvent stream:
(d) optionally periodically stopping and reversing the electric potential to cause movement of any fibrinogen having entered the membrane to move back into the first solvent stream, wherein substantially not causing any contaminants that have entered the second solvent stream to re-enter first solvent stream: and (e) maintaining step (c) until the first solvent stream contains the desired purity of fibrinogen substantially mimicking the clotting characteristics of natural fibrinogen.
2. The method according to claim 1 further including the steps of:
(f) replacing the first electrophoretic membrane with a second electrophoretic membrane having a molecular mass cut-off greater than that of the first membrane:
(g) applying an electric potential between the first and second solvent streams causing movement of at least some of the contaminants through the second membrane into the second solvent stream while the fibrinogen is substantially retained in the first solvent stream, or if entering the second membrane, being substantially prevented from entering the second solvent stream:
(h) optionally periodically stopping and reversing the electric potential to cause movement of any fibrinogen having entered the second membrane to move back into the first solvent stream, wherein substantially not causing any contaminants that have entered the second solvent stream to re-enter first solvent stream: and (i) maintaining step (g) until the first solvent stream contains the desired purity of fibrinogen substantially mimicking the characteristics of natural fibrinogen.
3. The method according to claim 1 or 2 wherein the mixture is a plasma fraction obtained from human blood containing fibrinogen, cryo-precipitate or solvent precipitate from human plasma.
4. The method according to any one of claims 1 to 3 wherein the first electrophoretic membrane has a molecular mass cut-off close to the apparent molecular mass of fibrinogen, and the second electrophoretic membrane has a molecular mass cut-off greater than the first electrophoretic membrane.
5. The method according to claim 4 wherein the first electrophoretic membrane has a molecular mass cut-off of 300 kDa and the second electrophoretic membrane has a molecular mass cut-off of 1000 kDa.
6. The method according to any one of claims 1 to 5 wherein the solvent streams have a pH of 7Ø
7. The method according to any one of claims 1 to 6 wherein recovery of fibrinogen is at least 70% and the fibrinogen having at least 95%
clottability.
8. Isolated fibrinogen substantially mimicking the clotting characteristics of natural fibrinogen purified by the method according to any one of claims 1 to 7.
9. Isolated fibrinogen substantially having the clotting and functional characteristics of natural fibrinogen.
10. Use of isolated fibrinogen according to claim 8 or 9 in medical and veterinary applications.
11. The use according to claim 10 selected from the group consisting of fibrin glue, isolating and characterising fibrinogen in dysfibrinogenaemias, inclusion in vascular grafts. and in wound healing aids.
12. A method of separating fibrinogen having a functional characteristic of natural fibrinogen from a mixture including fibrinogen and at least one contaminant. the fibrinogen and the at least one contaminant each having a respective size and a respective charge, the method comprising the steps of:
(a) exposing the mixture to an electric field in the presence of an electrophoretic membrane having a defined pore size to thereby separate at least a portion of the fibrinogen and the at least one contaminant onto opposite sides of the membrane in accordance with differences in at least one of the size and charge between the fibrinogen and the at least one contaminant;
(b) maintaining the exposing step for a period not greater than 48 hours;
and (c) recovering from the mixture not less than 50% of the fibrinogen content of the mixture.
13. A method of separating fibrinogen having a functional characteristic of natural fibrinogen from a mixture including fibrinogen and at least one contaminant, the fibrinogen and the at least one contaminant each having a respective size and a respective charge, the method comprising the steps of:
(a) exposing the mixture to an electric field in the presence of an electrophoretic membrane having a defined pore size to thereby separate at least a portion of the fibrinogen and the at least one contaminant onto opposite sides of the membrane in accordance with differences in at least one of the size and charge between the fibrinogen and the at least one contaminant;
(b) maintaining the exposing step for a period not greater than 48 hours;
and (c) recovering fibrinogen from the mixture, wherein in a clotting test the fibrinogen produces fibrins in a clot having a mass to length ratio similar to that obtained with normal plasma in the same clotting test.
14. A method of separating fibrinogen having a functional characteristic of natural fibrinogen from a mixture including fibrinogen and at least one contaminant, the fibrinogen and the at least one contaminant each having a respective size and a respective charge, the method comprising the steps of:
(a) exposing the mixture to an electric field in the presence of an electrophoretic membrane having a defined pore size to thereby separate at least a portion of the fibrinogen and the at least one contaminant onto opposite sides of the membrane in accordance with differences in at least one of the size and charge between the fibrinogen and the at least one contaminant:
(b) maintaining the exposing step for a period not greater than 48 hours;
and (c) recovering fibrinogen from the mixture, wherein in a clotting test the fibrinogen produces a clot having fibrin network compaction similar to that obtained with normal plasma in the same clotting test.
15. A method of separating fibrinogen having a functional characteristic of natural fibrinogen from a mixture including fibrinogen and at least one contaminant, the fibrinogen and the at least one contaminant each having a respective size and a respective charge, the method comprising the steps of:
(a) exposing the mixture to an electric field in the presence of an electrophoretic membrane having a defined pore size to thereby separate at least a portion of the fibrinogen and the at least one contaminant onto opposite sides of the membrane in accordance with differences in at least one of the size and charge between the fibrinogen and the at least one contaminant:
(b) maintaining the exposing step for a period not greater than 48 hours;
and (c) recovering fibrinogen from the mixture having a purity of not less than 90%.
16. The method according to any one of claims 12 to 15 wherein the mixture is a plasma fraction obtained from human blood containing fibrinogen, cryo-precipitate or solvent precipitate from human plasma.
CA002340106A 1998-08-12 1999-08-11 Purification of blood clotting proteins Abandoned CA2340106A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPP5212 1998-08-12
AUPP5212A AUPP521298A0 (en) 1998-08-12 1998-08-12 Purification of fibrinogen
PCT/AU1999/000653 WO2000009540A1 (en) 1998-08-12 1999-08-11 Purification of blood clotting proteins

Publications (1)

Publication Number Publication Date
CA2340106A1 true CA2340106A1 (en) 2000-02-24

Family

ID=3809444

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002340106A Abandoned CA2340106A1 (en) 1998-08-12 1999-08-11 Purification of blood clotting proteins

Country Status (6)

Country Link
US (1) US20050199498A1 (en)
EP (1) EP1105410A4 (en)
JP (1) JP2002522553A (en)
AU (2) AUPP521298A0 (en)
CA (1) CA2340106A1 (en)
WO (1) WO2000009540A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0216001D0 (en) 2002-07-10 2002-08-21 Nat Blood Authority Process and composition

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3878564A (en) * 1972-04-14 1975-04-22 Shang J Yao Blood and tissue detoxification method
US4043895A (en) * 1973-05-16 1977-08-23 The Dow Chemical Company Electrophoresis apparatus
DE2400164C3 (en) * 1974-01-03 1978-03-16 Bayer Ag, 5090 Leverkusen Process for the separation of 1,5-dinitroanthraquinone and 1,8-dinitroanthraquinone from dinitro-anthraquinone mixtures
DE2418996A1 (en) * 1974-04-19 1975-10-30 Bayer Ag ASYMMETRIC, SEMIPERMEABLE MEMBRANES MADE OF POLYBENZ-1,3-OXAZINDIONEN-2,4
DE2431071C2 (en) * 1974-06-28 1982-03-04 Bayer Ag, 5090 Leverkusen Asymmetrical, semipermeable membranes made of cyclic polyureas and their use for seawater desalination or for the separation and concentration of mixtures of substances
DE2536492A1 (en) * 1975-08-16 1977-02-24 Bayer Ag SEMIPERMEABLE MEMBRANES MADE OF SULFONIZED POLYBENZENE-1,3-OXAZINDIONEN- (2,4)
US4217227A (en) * 1975-12-06 1980-08-12 Bayer Aktiengesellschaft Semipermeable membranes of copolyamides
US4043896A (en) * 1976-03-25 1977-08-23 Aqua-Chem, Inc. Ultrafiltration and electrodialysis apparatus
ES462585A1 (en) * 1976-09-24 1978-07-16 Bauer Ag Semipermeable membranes of aromatic disulfimide containing polyamides
DE2713538A1 (en) * 1977-03-26 1978-09-28 Bayer Ag PROCESS FOR SEPARATION OF STEREOISOMER CYCLIC CARBONIC ACIDS
DE2719912C3 (en) * 1977-05-04 1979-12-06 Bayer Ag, 5090 Leverkusen Process for the isolation of 0- | 4,6-dideoxy-4- [JJl SO, 4,6 / 5) -4,5,6-trihydroxy-3-hydroxymethyl-2cyclohexen-1-yl] -amino] - a - D-glucopyranosyl} - (I right arrow 4) -0- a D-glucopyranosyl- (l right arrow 4) -D-glucopyranose from culture broths
US4115225A (en) * 1977-07-22 1978-09-19 Ionics, Inc. Electrodialysis cell electrode reversal and anolyte recirculation system
DE2741669A1 (en) * 1977-09-16 1979-03-22 Bayer Ag SEMIPERMEABLE MEMBRANES MADE FROM ACRYLONITRILE COPOLYMERIZED
WO1979000299A1 (en) * 1977-11-17 1979-05-31 Atomic Energy Authority Uk Purification of factor viii
US4362612A (en) * 1978-04-18 1982-12-07 University Patents, Inc. Isoelectric focusing apparatus
US4204929A (en) * 1978-04-18 1980-05-27 University Patents, Inc. Isoelectric focusing method
US4259079A (en) * 1978-04-21 1981-03-31 Blum Alvin S Method and apparatus for electrical separation of molecules
US4238306A (en) * 1979-02-14 1980-12-09 Research Products Rehovot Ltd. Electrodialysis process for the separation of non-essential amino acids from derivatives thereof
US4238307A (en) * 1979-02-14 1980-12-09 Research Products Rehovot Ltd. Electrodialysis process for the separation of essential amino acids from derivatives thereof
US4279724A (en) * 1979-07-18 1981-07-21 Hearn Milton T W Preparative electrofocusing in flat bed granulated polysaccharide gels
US4276140A (en) * 1980-01-10 1981-06-30 Ionics Inc. Electrodialysis apparatus and process for fractionating protein mixtures
US4351710A (en) * 1980-01-10 1982-09-28 Ionics, Incorporated Fractionation of protein mixtures
US4322275A (en) * 1980-01-10 1982-03-30 Ionics Incorporated Fractionation of protein mixtures
NO146013C (en) * 1980-05-13 1982-07-14 Ken Heimreid URINE LEAD DEVICE
US4299677A (en) * 1980-11-03 1981-11-10 The Hubinger Co. Process for the preferential separation of fructose from glucose
US4376023A (en) * 1980-11-03 1983-03-08 The Hubinger Company Process for the preferential separation of dextrose from oligosaccharides
US4441978A (en) * 1981-06-29 1984-04-10 Ionics Incorporated Separation of proteins using electrodialysis - isoelectric focusing combination
US4396477A (en) * 1981-06-29 1983-08-02 Ionics, Incorporated Separation of proteins using electrodialysis-isoelectric focusing combination
US4381232A (en) * 1981-08-24 1983-04-26 Ionics, Incorporated Multi-stage electrodialysis stack electrode reversal system and method of operation
US4533447A (en) * 1983-06-13 1985-08-06 Meldon Jerry H Apparatus for and method of isoelectric focussing
JPS6082106A (en) * 1983-10-12 1985-05-10 Ajinomoto Co Inc Method for preventing contamination of electrodialysis membrane
SE8402861L (en) * 1984-05-28 1985-11-29 Stefan Svenson PURIFICATION OF BIOLOGICAL MATERIAL
DE3434822A1 (en) * 1984-09-22 1986-04-03 Bayer Ag, 5090 Leverkusen MEMBRANE FOR REAGENT CARRIER LAYERS, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE IN ANALYTICAL AGENTS AND ANALYZING METHOD
US4661224A (en) * 1984-11-26 1987-04-28 Ionics, Incorporated Process and apparatus for electrically desorbing components selectively sorbed on an electrolytically conducting barrier
US4608140A (en) * 1985-06-10 1986-08-26 Ionics, Incorporated Electrodialysis apparatus and process
US4673483A (en) * 1986-03-20 1987-06-16 Ionics Incorporated Isoelectric focusing apparatus
US4897169A (en) * 1986-08-18 1990-01-30 Milan Bier Process and apparatus for recycling isoelectric focusing and isotachophoresis
DE3876273T2 (en) * 1987-04-11 1993-05-27 Ciba Geigy Ag ISOELECTRIC FOCUSING METHOD AND DEVICE FOR CARRYING OUT THIS METHOD.
US5043048A (en) * 1987-07-17 1991-08-27 Muralidhara Harapanahalli S Electromembrane apparatus and process for preventing membrane fouling
US5114555A (en) * 1988-01-05 1992-05-19 Monsanto Company Continuous isoelectric separation
GB2225339A (en) * 1988-11-15 1990-05-30 Aligena Ag Separating electrically charged macromolecular compounds by forced-flow membrane electrophoresis
US5160594A (en) * 1989-03-08 1992-11-03 Board Of Regents Of The University Of Texas System Apparatus and methods for isoelectric focusing of amphoteric substances incorporating ion selective membranes in electrode chambers
US4963236A (en) * 1989-03-08 1990-10-16 Ampholife Technologies Apparatus and methods for isoelectric focusing
DE3911065A1 (en) * 1989-04-06 1990-10-11 Bayer Ag METHOD FOR PRODUCING ALKALIDICHROMATES AND CHROME ACIDS BY ELECTROLYSIS
US5080770A (en) * 1989-09-11 1992-01-14 Culkin Joseph B Apparatus and method for separating particles
US5750015A (en) * 1990-02-28 1998-05-12 Soane Biosciences Method and device for moving molecules by the application of a plurality of electrical fields
DE4020051A1 (en) * 1990-06-23 1992-01-02 Bayer Ag Alkali di:chromate and chromic acid prodn. by electrolysis - in multi--compartment cell with bipolar ion exchange membrane to screen anode from chromium cpds.
US5336387A (en) * 1990-09-11 1994-08-09 Bioseparations, Inc. Electrical separator apparatus and method of counterflow gradient focusing
US5173164A (en) * 1990-09-11 1992-12-22 Bioseparations, Inc. Multi-modality electrical separator apparatus and method
GB2249741B (en) * 1990-10-06 1994-06-29 Univ Bradford Separation of the components of liquid dispersions
US5340449A (en) * 1990-12-07 1994-08-23 Shukla Ashok K Apparatus for electroelution
US5733442A (en) * 1990-12-07 1998-03-31 Shukla; Ashok K. Microdialysis/Microelectrodialysis system
US5122246A (en) * 1991-06-26 1992-06-16 Schmidt Joseph L Free flow electrophoresis method
US5185086A (en) * 1991-07-16 1993-02-09 Steven Kaali Method and system for treatment of blood and/or other body fluids and/or synthetic fluids using combined filter elements and electric field forces
DE4127861A1 (en) * 1991-08-22 1993-02-25 Bayer Ag LOW BASIC ANION EXCHANGER, METHOD FOR THE PRODUCTION THEREOF BY AMINOLYSIS AND THEIR USE FOR THE REMOVAL OF SULFATIONS FROM AQUEOUS LIQUIDS
DE4135847A1 (en) * 1991-10-31 1993-05-06 Bayer Ag, 5090 Leverkusen, De ASYMMETRIC, SEMIPERMEABLE MEMBRANES OF AROMATIC POLYCONDENSATES, METHOD FOR THEIR PRODUCTION AND THEIR USE
US5259971A (en) * 1992-03-02 1993-11-09 Cryolife, Inc. Method of preparing fibrinogen
DE4238389A1 (en) * 1992-11-13 1994-05-19 Bayer Ag Method for carrying out immunodiagnostic verifications
US5334300A (en) * 1992-12-08 1994-08-02 Osmotek, Inc. Turbulent flow electrodialysis cell
DE4319570A1 (en) * 1993-06-14 1994-12-15 Bayer Ag Process and separation of alkanols from other organic compounds with a higher carbon number
JP3423041B2 (en) * 1993-10-07 2003-07-07 三洋電機株式会社 Neural model element
DE4338196A1 (en) * 1993-11-09 1995-05-11 Bayer Ag Process for cleaning organic synthesis products
US5437774A (en) * 1993-12-30 1995-08-01 Zymogenetics, Inc. High molecular weight electrodialysis
DE4406952A1 (en) * 1994-03-03 1995-09-07 Bayer Ag Process for concentrating paint overspray
WO1995032052A1 (en) * 1994-05-20 1995-11-30 U.S. Filter/Ionpure, Inc. Polarity reversal and double reversal electrodeionization apparatus and method
US5561115A (en) * 1994-08-10 1996-10-01 Bayer Corporation Low temperature albumin fractionation using sodium caprylate as a partitioning agent
US5610285A (en) * 1994-08-24 1997-03-11 Bayer Corporation Purification of α-1 proteinase inhibitor using novel chromatographic separation conditions
US5662813A (en) * 1994-10-21 1997-09-02 Bioseparations, Inc. Method for separation of nucleated fetal erythrocytes from maternal blood samples
DE4438833A1 (en) * 1994-10-31 1996-05-02 Bayer Ag Method for the analytical separation of viruses
JPH11502764A (en) * 1995-03-23 1999-03-09 アイオニクス インコーポレイテッド Improvement of membrane treatment including electrodialysis
DE19546136A1 (en) * 1995-12-11 1997-06-12 Bayer Ag Chiral stationary phases for the chromatographic separation of optical isomers
CZ290229B6 (en) * 1995-12-15 2002-06-12 Bayer Aktiengesellschaft Multiphase extractor
US5938904A (en) * 1996-03-27 1999-08-17 Curagen Corporation Separation of charged particles by a spatially and temporally varying electric field
US5891736A (en) * 1996-06-21 1999-04-06 Bayer Corporation Reagents and methods for releasing and measuring lead ions from biological matrices
US5804420A (en) * 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
US5986075A (en) * 1999-01-20 1999-11-16 Bayer Corporation Process for the production of diazonium compounds with a low content of sodium ions
AUPP971399A0 (en) * 1999-04-12 1999-05-06 Life Therapeutics Limited Separation of plasma components

Also Published As

Publication number Publication date
US20050199498A1 (en) 2005-09-15
EP1105410A1 (en) 2001-06-13
AUPP521298A0 (en) 1998-09-03
WO2000009540A1 (en) 2000-02-24
AU736461B2 (en) 2001-07-26
EP1105410A4 (en) 2006-05-31
JP2002522553A (en) 2002-07-23
AU5365099A (en) 2000-03-06

Similar Documents

Publication Publication Date Title
Hjertén et al. Purification and characterization of two forms of a low-affinity Ca2+-ATPase from erythrocyte membranes
Van Mourik et al. Factor VIII, a series of homologous oligomers and a complex of two proteins
Bhakdi et al. Detection of amphiphilic proteins and peptides in complex mixtures. Charge-shift crossed immunoelectrophosis and two-dimensional charge-shift electrophoresis
Kita et al. Purification and characterization of a nuclear pore glycoprotein complex containing p62
Wadström et al. Studies on extracellular proteins from Staphylococcus aureus: VI. Production and purification of β-haemolysin in large scale
JPS6361318B2 (en)
Fried et al. [22] Water-soluble nonionic polymers in protein purification
EP1171451B1 (en) Separation of plasma components
Østerud et al. The production and availability of tissue thromboplastin in cellular populations of whole blood exposed to various concentrations of endotoxin: an assay for detection of endotoxin
Colten et al. Ultracentrifugation of the first component of complement: effects of ionic strength
Petersen et al. Epitope analysis of isoforms of the major allergen Phl p V by fingerprinting and microsequencing
US7060173B2 (en) Removal of biological contaminants
CN103476930A (en) Method for electrophoresing nucleic acids, method for concentrating and purifying nucleic acids, cartridge for nucleic acid electrophoresis, and method for producing cartridge for nucleic acid electrophoresis
AU736461B2 (en) Purification of blood clotting proteins
Zöller et al. Purification of human gastric proteases by immunoadsorbents: Pepsinogen I Group
Maudsley et al. Isolation and characterization of goat C-reactive protein
KR101839347B1 (en) Method for removing impurity proteins in exosome-included samples using carbon beads
Casillas et al. Chromatographic behaviour of clotting factors
US7077942B1 (en) Removal of biological contaminants
Pinder et al. Preparation and properties of human red-cell ankyrin
Stoltz et al. Study of amino groups of the human platelet membrane
JPH07508009A (en) Purification of kringle-containing proteins and especially t-PA
Kaersgaard et al. Isolation of the factor VIII–von Willebrand factor complex directly from plasma by gel filtration
Toussi et al. Polypeptide marker and disease patterns found while mapping proteins in ascitis
Sinor et al. The Rh antigen specificity of erythrocyte proteolipid

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued